Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at the 2022 Synuclein Meeting
12 avr. 2022 13h00 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., April 12, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted...
Helsinn Investment Fund Invests €1 Million in Gain Therapeutics
19 févr. 2019 02h30 HE
|
Helsinn Healthcare S.A.
Helsinn Investment Fund Invests €1 Million in Gain Therapeutics Luxembourg, February 19, 2019: Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of...